Gates Foundation Commits $50 Million to Vir Biotechnology for HIV Broadly Neutralising Antibody Functional Cure
In January 2022, the Gates Foundation committed $50 million to Vir Biotechnology — a $40 million equity stake through its Strategic Investment Fund and a $10 million grant — to advance broadly neutralising antibodies engineered to suppress HIV replication and provide a 'vaccinal effect.' The programme includes a clinical proof-of-concept trial in HIV-infected adults and preclinical malaria prevention research. Vir had previously developed the COVID-19 treatment sotrovimab with GSK; the new programme applies the same antibody engineering platform to HIV.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
IAVI HIV Vaccine Trials Backed by Gates Foundation CAVD Show First Proof-of-Concept for Broadly Neutralising Antibody Priming
Next →
Gates Foundation Pledges $912 Million to Global Fund — Largest-Ever Commitment to Fight HIV, TB, and Malaria by 2030
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
December 2025
Gates Foundation Pledges $100 Million to Global Financing Facility for Women's and Children's Health 2026–2030
On December 6, 2025, at the Universal Health Coverage High-Level Forum in Tokyo, the Gates Foundation pledged $100 million to the World Bank-hosted Global Financing Facility's 2026–2030 strategy for ending preventable deaths among women, children, and adolescents in LMICs. The pledge brings the foundation's total GFF commitment past $500 million since 2015. The GFF provides catalytic grant financing and technical assistance to strengthen LMIC health systems and expand quality access to health and nutrition services for the world's most vulnerable populations.
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.